Search Results - "Sanford, Ben L" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

by BAER, Maria R, GEORGE, Stephen L, ANASTASI, John, BLOOMFIELD, Clara D, LARSON, Richard A, CALIGIURI, Michael A, SANFORD, Ben L, BOTHUN, Sandra M, MROZEK, Krzysztof, KOLITZ, Jonathan E, POWELL, Bayard L, MOORE, Joseph O, STONE, Richard M
Published in Journal of clinical oncology (20.10.2008)

Get full text

Journal Article

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

by Choueiri, Toni K, Halabi, Susan, Sanford, Ben L, Hahn, Olwen, Michaelson, M Dror, Walsh, Meghara K, Feldman, Darren R, Olencki, Thomas, Picus, Joel, Small, Eric J, Dakhil, Shaker, George, Daniel J, Morris, Michael J
Published in Journal of clinical oncology (20.02.2017)

Get full text

Journal Article

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

by Stone, Richard M, Mandrekar, Sumithra J, Sanford, Ben L, Laumann, Kristina, Geyer, Susan, Bloomfield, Clara D, Thiede, Christian, Prior, Thomas W, Döhner, Konstanze, Marcucci, Guido, Lo-Coco, Francesco, Klisovic, Rebecca B, Wei, Andrew, Sierra, Jorge, Sanz, Miguel A, Brandwein, Joseph M, de Witte, Theo, Niederwieser, Dietger, Appelbaum, Frederick R, Medeiros, Bruno C, Tallman, Martin S, Krauter, Jürgen, Schlenk, Richard F, Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Larson, Richard A, Döhner, Hartmut
Published in The New England journal of medicine (03.08.2017)

Get full text

Journal Article

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

by Larson, Richard A., Mandrekar, Sumithra J., Huebner, Lucas J., Sanford, Ben L., Laumann, Kristina, Geyer, Susan, Bloomfield, Clara D., Thiede, Christian, Prior, Thomas W., Döhner, Konstanze, Marcucci, Guido, Voso, Maria Teresa, Klisovic, Rebecca B., Galinsky, Ilene, Wei, Andrew H., Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, Theo, Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C., Tallman, Martin S., Krauter, Jürgen, Schlenk, Richard F., Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Gathmann, Insa, Döhner, Hartmut, Stone, Richard M.
Published in Leukemia (01.09.2021)

Get full text

Journal Article

Application of multi-state models in cancer clinical trials

Application of multi-state models in cancer clinical trials

by Le-Rademacher, Jennifer G, Peterson, Ryan A, Therneau, Terry M, Sanford, Ben L, Stone, Richard M, Mandrekar, Sumithra J
Published in Clinical trials (London, England) (01.10.2018)

Get more information

Journal Article

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

by Wetzler, Meir, Sanford, Ben L., Kurtzberg, Joanne, DeOliveira, Divino, Frankel, Stanley R., Powell, Bayard L., Kolitz, Jonathan E., Bloomfield, Clara D., Larson, Richard A.
Published in Blood (15.05.2007)

Get full text

Journal Article

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

by Klepin, Heidi D., Ritchie, Ellen, Major-Elechi, Brittny, Le-Rademacher, Jennifer, Seisler, Drew, Storrick, Libby, Sanford, Ben L., Marcucci, Guido, Zhao, Weiqiang, Geyer, Susan A., Ballman, Karla V., Powell, Bayard L., Baer, Maria R., Stock, Wendy, Cohen, Harvey Jay, Stone, Richard M., Larson, Richard A., Uy, Geoffrey L.
Published in Journal of geriatric oncology (01.01.2020)

Get full text

Journal Article

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series

by Mohler, James L., Halabi, Susan, Ryan, Stephen T., Al-Daghmin, Ali, Sokoloff, Mitchell H., Steinberg, Gary D., Sanford, Ben L., Eastham, James A., Walther, Philip J., Morris, Michael J., Small, Eric J.
Published in Prostate cancer and prostatic diseases (01.05.2019)

Get full text

Journal Article

Long‐term outcomes for newly‐diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

Long‐term outcomes for newly‐diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

by Voorhees, Peter M., Orlowski, Robert Z., Mulkey, Flora, Watson, Peter, Geyer, Susan, Sanford, Ben L., Bennett, Elizabeth, Chanan‐Khan, Asher A., Bloomfield, Clara D., Larson, Richard A.
Published in British journal of haematology (01.11.2015)

Get full text

Journal Article

A phase II trial of cisplatin, fixed dose‐rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102

A phase II trial of cisplatin, fixed dose‐rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102

by Philips, George K., Halabi, Susan, Sanford, Ben L., Bajorin, Dean, Small, Eric J.
Published in BJU international (01.01.2008)

Get full text

Journal Article

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)

by Gupta, Pankaj, Mulkey, Flora, Hasserjian, Robert P., Sanford, Ben L., Vij, Ravi, Hurd, David D., Odenike, Olatoyosi M., Bloomfield, Clara D., Owzar, Kouros, Stone, Richard M., Larson, Richard A.
Published in Investigational new drugs (01.10.2013)

Get full text

Journal Article

PD27-09 MANAGEMENT OF RECURRENT PROSTATE CANCER AFTER RADIOTHERAPY: LONG-TERM RESULTS FROM CALGB 9687, A CONTEMPORARY PROSPECTIVE MULTI-INSTITUTIONAL SALVAGE PROSTATECTOMY SERIES

PD27-09 MANAGEMENT OF RECURRENT PROSTATE CANCER AFTER RADIOTHERAPY: LONG-TERM RESULTS FROM CALGB 9687, A CONTEMPORARY PROSPECTIVE MULTI-INSTITUTIONAL SALVAGE PROSTATECTOMY SERIES

by AL-Daghmin, Ali, Sokoloff, Mitchell H, Steinberg, Gary D, Halabi, Susan, Sanford, Ben L, Eastham, James A, Walther, Philip J, Small, Eric J, Mohler, James L
Published in The Journal of urology (01.04.2014)

Get full text

Journal Article

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)

by Blum, W, Sanford, B L, Klisovic, R, DeAngelo, D J, Uy, G, Powell, B L, Stock, W, Baer, M R, Kolitz, J E, Wang, E S, Hoke, E, Mrózek, K, Kohlschmidt, J, Bloomfield, C D, Geyer, S, Marcucci, G, Stone, R M, Larson, R A
Published in Leukemia (01.01.2017)

Get full text

Journal Article

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial

by George, Daniel J., Hessel, Colin, Halabi, Susan, Sanford, Ben L., Michaelson, M. Dror, Hahn, Olwen Mary, Walsh, Meghara K., Olencki, Thomas, Picus, Joel, Small, Eric Jay, Dakhil, Shaker R., Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, Morris, Michael J., Choueiri, Toni K.
Published in Journal of clinical oncology (20.02.2018)

Get full text

Journal Article

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

by Larson, Richard A., Mandrekar, Sumithra J, Sanford, Ben L., Laumann, Kristine, Geyer, Susan M., Bloomfield, Clara D., Thiede, Christian, Prior, Thomas W, Dohner, Konstanze, Marcucci, Guido, Lo Coco, Francesco, Klisovic, Rebecca B., Wei, Andrew, Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, T. M. M, Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C, Tallman, Martin S., Krauter, Jurgen, Schlenk, Richard F., Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Döhner, Hartmut, Stone, Richard M.
Published in Blood (08.12.2017)

Get full text

Journal Article

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

by Stone, Richard M., Mandrekar, Sumithra J, Sanford, Ben L., Laumann, Kristine, Geyer, Susan M., Bloomfield, Clara D., Dohner, Konstanze, Thiede, Christian, Marcucci, Guido, Lo Coco, Francesco, Klisovic, Rebecca B., Wei, Andrew, Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, T. M. M, Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C, Tallman, Martin S., Krauter, Jurgen, Schlenk, Richard F., Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Dohner, Hartmut, Larson, Richard A.
Published in Blood (08.12.2017)

Get full text

Journal Article

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

by Döhner, Konstanze, Thiede, Christian, Larson, Richard A., Prior, Thomas W, Marcucci, Guido, Jones, Dan, Krauter, Jürgen, Heuser, Michael, Lo Coco, Francesco, Ottone, Tiziana, Nomdedeu, Josep, Mandrekar, Sumithra J, Sanford, Ben L., Laumann, Kristine, Geyer, Susan M., Klisovic, Rebecca B., Wei, Andrew, Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, T. M. M, Jansen, Joop H., Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C, Tallman, Martin S., Schlenk, Richard F., Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Cheng, Yuan, Pallaud, Celine, Stone, Richard M., Döhner, Hartmut, Bloomfield, Clara D.
Published in Blood (08.12.2017)

Get full text

Journal Article

The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])

The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])

by Stone, Richard M., Mandrekar, Sumithra, Sanford, Ben L, Geyer, Susan, Bloomfield, Clara D., Dohner, Konstanze, Thiede, Christian, Marcucci, Guido, Lo-Coco, Francesco, Klisovic, Rebecca B., Wei, Andrew, Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, Theo, Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C., Tallman, Martin S, Krauter, Jurgen, Schlenk, Richard F., Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Larson, Richard A., Dohner, Hartmut
Published in Blood (03.12.2015)

Get full text

Journal Article

Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance)

Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance)

by Klepin, Heidi D., Ritchie, Ellen K., Sanford, Ben L., Marcucci, Guido, Zhao, Weiqiang, Geyer, Susan Michelle, Ballman, Karla V., Powell, Bayard L., Baer, Maria R., Stock, Wendy, Cohen, Harvey Jay, Stone, Richard M., Larson, Richard A., Uy, Geoffrey L.
Published in Journal of clinical oncology (20.05.2014)

Get full text

Journal Article

Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)

Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)

by Smith, Matthew Raymond, Halabi, Susan, Ryan, Charles J., Stadler, Walter Michael, Hussain, Arif, Vogelzang, Nicholas J., Hauke, Ralph J., Sanford, Ben L., Small, Eric Jay
Published in Journal of clinical oncology (20.02.2013)

Get full text

Journal Article